Cabazitaxel
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
- Cabazitaxel
- Cabazitaxel: From Metastatic Castration-Resistant Prostate Cancer to Female Breast Carcinoma
Cabazitaxel: From Metastatic Castration-Resistant Prostate Cancer to Female Breast Carcinoma
One-Sentence Summary
Cabazitaxel is a second-generation taxane originally developed for metastatic castration-resistant prostate cancer (mCRPC) after docetaxel failure. The TxGNN model predicts it may also be effective for Female Breast Carcinoma, with 0 registered clinical trials matched to this indication but 20 supporting publications — including one completed Phase II RCT directly testing cabazitaxel in breast cancer — currently backing this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Metastatic castration-resistant prostate cancer (per literature evidence in this pack; official Finnish label text unavailable — drug is not marketed in Finland) |
| Predicted New Indication | Female Breast Carcinoma |
| TxGNN Prediction Score | 99.92% |
| Evidence Level | L2 |
| Finland Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Formal DrugBank mechanism-of-action data is not available for cabazitaxel in this evidence pack. Based on information contained in the literature evidence, cabazitaxel is a second-generation taxane and microtubule-stabilizing antimitotic agent: it binds tubulin to stabilize microtubules and arrest mitosis, in the same manner as docetaxel and paclitaxel, but was specifically engineered to reduce affinity for P-glycoprotein (P-gp) efflux pumps, giving it activity in taxane-resistant tumor cell lines (PMID 25416788, 26651178).
Cabazitaxel's original indication (mCRPC) and the predicted new indication (breast carcinoma) are both solid tumors for which taxane-class chemotherapy (paclitaxel, docetaxel) is already a clinical standard of care. Cabazitaxel's improved resistance profile is mechanistically relevant to breast cancer, where acquired resistance to earlier-generation taxanes is a recognized clinical problem.
This is not purely theoretical: a completed Phase II RCT (GENEVIEVE, PMID 28768217) already compared neoadjuvant cabazitaxel against weekly paclitaxel in operable triple-negative and luminal B/HER2-negative breast cancer, and a Phase I/II dose-escalation study (PMID 21339064) tested cabazitaxel plus capecitabine in metastatic breast cancer after anthracycline/taxane failure — indicating clinical-stage investigation of this indication already exists, beyond model prediction alone.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 28768217 | 2017 | RCT (Phase II) | European Journal of Cancer | GENEVIEVE study: randomised neoadjuvant cabazitaxel vs weekly paclitaxel in operable TNBC/luminal B/HER2-negative breast cancer, comparing pathological complete response rates |
| 21339064 | 2011 | Phase I/II (dose-escalation) | European Journal of Cancer | Cabazitaxel + capecitabine in metastatic breast cancer progressing after anthracycline/taxane treatment; established MTD, PK, and safety profile |
| 33753567 | 2021 | Preclinical (mechanistic) | Journal for ImmunoTherapy of Cancer | Cabazitaxel modulates tumor-associated macrophages, enhancing CD47-targeted immunotherapy efficacy in triple-negative breast cancer models |
| 25416788 | 2015 | Preclinical (resistance mechanisms) | Molecular Cancer Therapeutics | Characterized cabazitaxel resistance in MCF-7 breast cancer cell-derived resistant variants; showed lower cross-resistance than paclitaxel/docetaxel |
| 33247980 | 2021 | Review (PK/TDM) | British Journal of Clinical Pharmacology | Review of taxane pharmacology including cabazitaxel PK/PD and therapeutic drug monitoring considerations |
| 26651178 | 2016 | Review (pharmacology/patents) | Expert Opinion on Therapeutic Patents | Reviews taxane development including cabazitaxel; notes related taxane nab-paclitaxel's approval for refractory/metastatic breast cancer |
| 30529259 | 2019 | Preclinical (PDX model) | Journal of Controlled Release | Cabazitaxel-loaded PEBCA nanoparticles achieved complete remission in 6/8 basal-like breast cancer patient-derived xenografts, outperforming free drug |
| 28504249 | 2017 | Preclinical (drug delivery) | Acta Pharmacologica Sinica | Cabazitaxel-loaded polymeric micelles showed enhanced anti-metastatic efficacy in breast cancer metastasis models |
| 30521787 | 2019 | Preclinical (drug delivery) | Chemistry and Physics of Lipids | Cabazitaxel + thymoquinone co-loaded lipospheres developed as a synergistic combination targeting p53/STAT3/Bax/BCL-2 pathways in breast cancer |
| 33360926 | 2021 | Preclinical (drug delivery) | Colloids and Surfaces B: Biointerfaces | Cabazitaxel-loaded nanostructured lipid carriers (NLCs) optimized and evaluated against breast cancer cell lines |
Finland Market Information
Cabazitaxel is not currently marketed in Finland — no marketing authorizations are registered (0 licenses on file).
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Conventional cytotoxic (taxane class, microtubule-stabilizing antimitotic agent) |
| Myelosuppression Risk | High — neutropenia is reported as one of the most common adverse effects of cabazitaxel in the literature (PMID 21076710) |
| Emetogenicity Classification | Please refer to the package insert |
| Monitoring Items | CBC with differential (neutropenia), peripheral neuropathy assessment, renal and hepatic function |
| Handling Protection | Standard cytotoxic drug handling precautions required (PPE, closed-system transfer device) |
Safety Considerations
Please refer to the package insert for safety information. (TFDA/Fimea label warnings, contraindications, and drug interaction data are currently unavailable — flagged as a blocking data gap for formal safety review.)
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Mechanistic plausibility is supported by the established role of taxanes in breast cancer treatment, and this specific indication already has clinical-stage investigation — one completed Phase II RCT (GENEVIEVE) and one Phase I/II dose-escalation study — rather than being purely a model prediction. However, no clinical trials are currently indexed against this exact indication, and Finnish regulatory/safety data are entirely absent, justifying guardrails rather than an unconditional Go.
To proceed, the following is needed:
- Official package insert / label safety data (warnings, contraindications, DDI) — currently a blocking data gap
- Confirmed DrugBank mechanism-of-action record
- Efficacy outcomes from the GENEVIEVE trial (PMID 28768217) and the Phase I/II capecitabine combination study (PMID 21339064)
- A breast cancer-specific safety monitoring plan addressing myelosuppression and neuropathy risk, given the drug is not currently marketed in Finland
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.